| __timestamp | Alnylam Pharmaceuticals, Inc. | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 7890000 |
| Thursday, January 1, 2015 | 60610000 | 14456000 |
| Friday, January 1, 2016 | 89354000 | 19218000 |
| Sunday, January 1, 2017 | 199365000 | 27986000 |
| Monday, January 1, 2018 | 382359000 | 47928000 |
| Tuesday, January 1, 2019 | 479005000 | 96388000 |
| Wednesday, January 1, 2020 | 588420000 | 157743000 |
| Friday, January 1, 2021 | 620639000 | 195293000 |
| Saturday, January 1, 2022 | 770658000 | 237374000 |
| Sunday, January 1, 2023 | 795646000 | 295141000 |
| Monday, January 1, 2024 | 975526000 | 359272000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, operational efficiency is paramount. Alnylam Pharmaceuticals, Inc. and Blueprint Medicines Corporation, two titans in the field, have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive expansion and strategic investments. In contrast, Blueprint Medicines exhibited a more measured growth of approximately 3,600%, indicating a steady scaling of operations. Notably, by 2023, Alnylam's SG&A expenses were nearly three times higher than Blueprint's, underscoring its larger operational scale.
This analysis highlights the divergent strategies of these companies in managing operational costs, offering insights into their financial health and strategic priorities. As the biotech sector continues to evolve, understanding these trends is crucial for investors and industry stakeholders.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Pfizer Inc. and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Blueprint Medicines Corporation
Insmed Incorporated and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Madrigal Pharmaceuticals, Inc.
Blueprint Medicines Corporation and MorphoSys AG: SG&A Spending Patterns Compared
Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Galapagos NV
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Xencor, Inc.